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ABSTRACT
Cardiomyocytes are notoriously difficult to transfect using standard techniques unless viral vectors such as
recombinant adenoviruses are used. Generation of recombinant adenoviruses is, however, a complex and time-
consuming procedure and not possible for every DNA construct. We therefore optimized DNA/polylysine/ade-
novirus complexing for efficient gene transfer in neonatal rat cardiomyocytes determining the critical para-
meters for this method. Importantly, not only the concentration of the various components but also the method
used for plasmid purification is critical for this transfection technique. Cesium–chloride-purified DNA is in-
ferior to anion-exchange methods for this purpose possibly because of altered ionic properties. In the second
part of this study, we could demonstrate silent gene transfer into cardiomyocytes applying this optimized tech-
nique to plasmids encoding luciferase or -galactosidase cDNAs under the control of the cytomegalovirus im-
mediate-early promoter. Phorbol myristate acetate and/or forskolin increased the amount of -galactosidase
positive cells up to fivefold. Luciferase activity could even be increased as much as ninefold. These results
demonstrate that the cytomegalovirus promoter is not maximally active in neonatal rat cardiomyocytes un-
der basal conditions. In fact, a large proportion of cells is silently transfected and seems to express (an) in-
hibitor(s) of transcription from the CMV promoter that can be overcome by stimulation of cAMP- or pro-
tein kinase C-dependent pathways.
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INTRODUCTION
CARDIOMYOCYTES ARE GENERALLY considered to be one ofthe most difficult cell types to transfect both in vitro and
in vivo. Recent advances in the construction of genetically en-
gineered adenovirus vectors have facilitated gene transfer into
both adult (Stratford-Perricaudet et al., 1992; Kirshenbaum et
al., 1993) and neonatal rat cardiomyocytes (nCMCs) (Kass-
Eisler et al., 1993) in vitro as well as into neonatal (Zhang et
al., 1999) and adult myocardium (Barr et al., 1994) in vivo.
Construction of adenoviral vectors, however, is a time-con-
suming technique and not possible for all potential transgenes.
Another major limitation of these vectors is the size constraint
for the introduction of a transgene including the promoter, es-
pecially for large cDNAs such as dystrophin or the ryanodine
receptor. For tissue-specific expression, longer promoters (in
the range of several kb) are usually used adding to the problem
of limited packaging capacity. Further problems include po-
tential toxicity to the parent cell line used to generate and am-
plify the virus thereby inhibiting production of recombinant
viruses. So far, no convincing technique has been established
to overcome this problem. An important application of plasmid
DNA transfer is the use of numerous constructs for the identi-
fication of regulatory gene elements. It would be very cumber-
some to generate recombinant adenoviruses for the numerous
constructs required.
We therefore evaluated a system that takes advantage of the
efficient gene transfer capabilities of adenoviruses but obviates
the construction of recombinant adenoviruses by a simple non-
covalent complex of adenovirus and plasmid DNA with polyly-
sine (Kohout et al., 1996). This technique has initially been in-
troduced by experiments by E. Wagner’s and D.T. Curiel’s
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groups (for review, see Michael and Curiel, 1994). It is feasi-
ble for large constructs such as cosmid DNA (Cotton et al.,
1992), and might even be extended to YAC transfection
(Marschall et al., 1999).
The most commonly used promoters in gene transfer exper-
iments are of viral origin, since they have evolved for optimal
gene expression in their host cells. One of the most commonly
used is the cytomegalovirus (CMV) immediate-early promoter,
which is considered to be among the strongest constitutive pro-
moters in most cells. Recent publications, however, have sug-
gested that there is regulation of this promoter in various cell
types (Clesham et al., 1996) including primary cardiac cells
(Maass et al., 2003).
In addition to the adaptation of the method of adenovirus/
polylysine/DNA complexing for primary rat cardiomyocytes,
this study confirms a surprising extent of regulation of the
CMV promoter in a plasmid background that is important to
consider when using this promoter in gene transfer experi-
ments.
MATERIALS AND METHODS
Isolation and culture of neonatal rat CMCs
Hearts of 1–3-day-old rats were excised and cardiomyocytes
were isolated by trypsin digestion as previously described
(Maass et al., 2003). Cells were cultured in serum-free MEM
supplemented with transferrin, insulin, and BSA for 24–48 h
before experiments were carried out.
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FIG. 1. Optimization of gene transfer by adenovirus/polylysine/DNA complexing in neonatal rat cardiomyocytes assessed by
luciferase activity. (a) Complexing of variable amounts of plasmid DNA with polylysine and adenovirus. Relative luciferase ac-
tivity normalized to cells transfected with a concentration of 2 g DNA per ml of culture media. Polylysine constant at 2 g/ml,
adenovirus constant at 5  1010 particles/ml. n  5 for all concentrations. (b) Complexing of variable amounts of polylysine with
2 g plasmid DNA and adenovirus. Luciferase activity normalized to cells transfected with 2 g polylysine per ml of culture
media. DNA constant at 2 g/ml, adenovirus constant at 5  1010 particles/ml. n  5 for all concentrations. (c) Luciferase ac-
tivity normalized to protein content in the sample after complexing with increasing amounts of adenovirus particles using five
different adenovirus preparations (labeled by different symbols , , , , ). (d) Luciferase activity using plasmid DNA pre-
pared by different isolation techniques. Qiagen: plasmid DNA prepared by a commercial kit, 1  CsCl: plasmid DNA prepared
after alkaline lysis and single banding on a CsCl gradient, 2  CsCl: plasmid DNA banded twice on a CsCl gradient. n  4 for
each DNA preparation. Significances calculated versus Qiagen DNA.
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below 5% and we therefore wanted to determine critical para-
meters that had not been published previously (Kohout et al.,
1996). The first variable we tested was DNA concentration at
a constant DNA/polylysine ratio and a constant amount of ade-
novirus. There was a sharp maximum at a DNA dose of 2–3
g/ml media with luciferase activity decreasing rapidly at
higher and lower DNA concentrations (Fig. 1a). The second
variable was the polylysine to DNA ratio. Keeping the DNA
concentration constant at 2 g/ml, we tested polylysine con-
centrations from 0.2 to 12 g/ml media. There was a sharp op-
timum at a polylysine concentration of 2 g/ml, with luciferase
activity again falling rapidly at higher or lower concentrations
(Fig. 1b). The third variable tested was the amount of viral par-
ticles in the complexes. The results differed dramatically for
different preparations of the virus (Fig. 1c). There was a steady
increase for most of the different virus preparations without
reaching a maximum even at 2  1011 virus particles per mil-
liliter of media. There was no correlation between infectious
particles as assessed by plaque assays and the efficiency of
transfection (data not shown), and in all further experiments we
used the photometrically determined amount of virus particles
to calculate the appropriate amount for each transfection. The
maximum amounts of adenovirus used in this study corre-
sponded to a multiplicity of infection of 5  104 plaque form-
ing units per cell, a concentration that is generally considered
toxic to cells. We could, however, not detect any toxic effects
on our cells as assessed by conversion of the formazan dye MTT
(data not shown). This could be explained by the use of a re-
combinant virus not encoding for any transgene or promoter el-
ements that might be toxic at higher doses.
It has been speculated that supercoiled plasmid DNA is re-
quired for efficient gene transfer. To ensure high quality of our
plasmid DNA, we generally purified the DNA by double ce-
sium chloride (CsCl) banding followed by dialysis to remove
remaining CsCl. We compared this method with single CsCl
banding and a commercially available kit for plasmid DNA iso-
lation utilizing anion exchange (Qiagen). Surprisingly, there
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FIG. 2. Gel retardation assay of plasmid DNA complexed with
increasing amounts of polylysine. Left half: plasmid DNA puri-
fied by CsCl gradients. Right half: plasmid DNA purified by an-
ion exchange (Qiagen). Slots: slots of agarose gel where
DNA/polylysine complex was loaded. Circ, circular form of the
plasmid; S.coiled, supercoiled form of the plasmid; PL, polylysine.
Luciferase and -galactosidase assays
After the indicated incubation period, cells were washed
twice with phosphate buffered saline (PBS) and lysed in 1
passive lysis buffer (Promega, Madison, WI). Protein concen-
trations were measured by the modified Bradford method (Bio-
Rad, Hercules, CA) and luciferase activity determined after
mixing with 100 l assay reagent (Promega) in a standard lu-
minometer (Turner Designs, Sunnyvale, CA). Relative light
units (RLU) were normalized to microgram protein content in
the sample. Cells transfected with -galactosidase containing
constructs were washed twice with PBS, fixed for 10 min in
2% formaldehyde, and stained in potassium ferricyanide/potas-
sium ferrocyanide and X-gal overnight. -Galactosidase posi-
tive cells were counted by phase-contrast microscopy.
Adenovirus/polylysine complexing
Replication-deficient adenovirus (Addl312) was grown by
standard methods as previously described (Maass et al., 2003).
Briefly, HEK293 cells (ATCC, Rockville, MD) were infected,
and virus was harvested after 24 h with freeze/thaw cycles.
Virus was purified over a cesium chloride gradient, dialyzed,
and stored at 20°C in storage buffer containing glycerol. Par-
ticle numbers were determined photometrically.
Plasmid DNA was isolated either by a commercially avail-
able kit (Qiagen, Hilden, Germany) or by standard cesium chlo-
ride banding (one or two rounds of purification) followed by
dialysis and precipitation. Poly-L-lysine with an average mo-
lecular weight of 35 kDa (Sigma, St. Louis, MO) was used as
a stock solution of 33 g/ml in MEM. Two-thirds of the total
poly-L-lysine (optimal dose 1.33 g) was mixed with aden-
ovirus (1011 particles) in 200 l MEM and incubated for 30
min. Plasmid DNA (2 g) was added, and after a further 30-
min incubation the remaining third of polylysine (0.6 g) was
added. The complex was incubated for 10 min before it was
added to the cells in serum-free MEM.
RESULTS
Initial experiments using adenovirus/polylysine/plasmid
complexes in neonatal rat cardiomyocytes showed efficiencies
FIG. 3. Stimulation of luciferase activity with forskolin and
phorbol-myristate-acetate (PMA) for 48 h at different concen-
trations 18 h after transfection. Logarithmic scale with numbers
representing the log concentration (e.g., 6: 106 M). Co, con-
trol, no stimulation. Significances versus control. n.s., no sig-
nificance.
was a significant decrease in luciferase activity when we used
CsCl purified DNA (Fig. 1d). A possible explanation might lie
in structural differences in plasmid DNA prepared by different
methods. The precise structural requirements for DNA used in
different transfection techniques have not been elucidated. In
some cases such as direct injection in vivo, supercoiled DNA
seems to be more efficient (Buvoli and Leinwand, 2002). Both
methods that were employed yielded almost exclusively super-
coiled DNA (Fig. 2). The major difference between the anion-
exchange method and CsCl purification is the amount of en-
dotoxin in the preparation, which is much lower for CsCl
(Wicks et al., 1995). We therefore compared an endotoxin low-
ering kit (Endo-free Qiagen kit) with no difference to the reg-
ular kit (data not shown). To further elucidate the mechanism
of better performance of DNA produced by the ion-exchange
method, we complexed equal amounts of each DNA with in-
creasing amounts of polylysine and separated them by agarose
gel electrophoresis. Surprisingly, for CsCl-purified DNA more
polylysine was needed to retard migration into the gel. This re-
sult suggests a lower binding affinity of CsCl-purified DNA for
polylysine (Fig. 2).
When assaying transfection efficiency at our optimized con-
ditions with -galactosidase encoding plasmids, the amount of
visibly transfected cells (by positive -galactosidase staining)
was approximately 10%. This is in stark contrast to the results
from Kohout et al. (1996) reporting transfection efficiencies of
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FIG. 4. Increase in percentage of -galactosidase-positive
neonatal rat cardiomyocytes after transfection with plasmid/
polylysine/adenovirus complexes. (a) Percentage of beta-galac-
tosidase positive neonatal rat cardiomyocytes after transfection
for 18 h and subsequent treatment with Forskolin (106 M)
and/or phorbol-myristate-acetate (PMA, 106 M) for 48 h. Co,
control, no stimulation. n  5 independent experiments. Sig-
nificances calculated versus control. (b) Representative pho-
tographs of neonatal rat cardiomyocytes after transfection for
18 h (Co) and treatment with PMA (106 M), or both PMA
and Forskolin (106 M) for 48 h.
a
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up to 50%. A possible explanation for this discrepancy might
lie in the different culture conditions used. In contrast to other
investigators (Kohout et al., 1996), we cultured our cells in con-
ditions that do not promote autonomous hypertrophy, that is,
serum-free conditions (Simpson et al., 1982). Serum contains
a suite of growth-inducing factors, some of which might also
act as transcriptional activators of the CMV early promoter
(Ghazal et al., 1987). We sought to identify possible signal
transduction pathways that can activate the CMV early pro-
moter in neonatal rat CMCs. Four repeat elements have been
described that occur four to six times each in the CMV imme-
diate-early promoter (Ghazal et al., 1997): A 17-bp element
with an NF1 half site, an 18-bp element binding NFB (Niller
and Hennighausen, 1991), a 19bp element containing a cAMP
response element (Stamminger et al., 1990), and a 21 bp ele-
ment binding YY1 (Liu et al., 1994). An up to 23-fold activa-
tion of the CMV promoter by forskolin and phorbol ester has
been discovered in human vascular smooth muscle cells (Cle-
sham et al., 1996), accompanied with an identification of silent
gene transfer in these cells.
We used two defined inducers of different signal transduc-
tion pathways to assay activation of the CMV promoter in
neonatal rat CMCs after transfection with DNA/polylysine/ade-
novirus complexes. PMA was used to stimulate protein kinase
C and its downstream effectors. Forskolin was used to activate
cAMP and its downstream effectors protein kinase A and
CREBP.
Forskolin dose dependently increased luciferase activity up
to fivefold after transfection of the complex (Fig. 3). PMA also
induced luciferase activity dose dependently up to fourfold (Fig.
3). Both substances acted additively, inducing luciferase activ-
ity up to ninefold (Fig. 3). Interestingly, when we assayed the
number of cells visibly expressing -galactosidase, this num-
ber increased after the use of forskolin and PMA from 10% in
control cells to 50% when using both substances (Fig. 4), sug-
gesting that the number of cells being transfected in the un-
stimulated state was underestimated because of transgene ex-
pression below the detectable limit.
To assess if the observed promoter induction was restricted
to the CMV promoter, we tested both a different viral (the Rous
Sarcoma Virus promoter) and a muscle-specific promoter
(MEF2-responsive promoter) (Maass et al., 2003). These ex-
hibited a slightly higher basal activity but were only minimally
inducible by PMA and/or forskolin (Fig. 5). When staining with
a luciferase-specific antibody, we could detect robust expres-
sion only in about 10% of the cells, similar to the uninduced
CMV promoter (data not shown).
DISCUSSION
Gene transfer to the myocardium is of obvious scientific and
potentially therapeutic interest, but has proved notoriously dif-
ficult. This study therefore aimed at more precisely defining pa-
rameters that are critical for using a technically simple method,
noncovalent adenovirus/polylysine/plasmid DNA complexing,
for gene transfer into cardiomyocytes. This technique has been
summarily described (Kohout et al., 1996) but has not been
used widely because of rather variable results. Defining the pa-
rameters governing this variability may therefore contribute to
a wider application, potentially even in (animal) experiments
of therapeutic gene transfer methods.
Critical parameters defined in this study are both DNA and
polylysine concentrations that showed a very sharp peak at 2
g/ml media. Some virus preparations proved more efficient
than others independent from infectivity, suggesting the neces-
sity of testing several preparations to find the optimal batch.
CsCl purified DNA proved inferior to plasmid made by a com-
mercially available kit. We showed that this surprising result is
not due to different molecular forms, as both methods yield
mainly supercoiled plasmid DNA. This finding also cannot be
explained by contaminating endotoxin, since that should lead
to the opposite effect of better performance by CsCl-purified
DNA that contains low levels of endotoxin. Our hypothesis is
that the methods for plasmid purification lead to DNA with dif-
ferent ionic properties. This hypothesis is strengthened by the
gel retardation assay that shows that the equal amount polyly-
sine binds less CsCl-purified DNA than DNA purified by an-
ion exchange (Fig. 2). The different ionic properties can be ex-
plained by the method employed by currently available kits to
purify plasmid DNA. The anion exchange technique favors
DNA with the maximal number of available negative charges.
This property is obviously critical for binding the positively
charged polylysine.
A very important finding is the up to ninefold induction of
the CMV promoter, but not the RSV or MEF2-responsive pro-
moters in cardiomyocytes by PMA and forskolin. This demon-
strates that, other than previously thought, even a strong viral
promoter might not be maximally active in these cells under
basal conditions. This phenomenon is not restricted to the cells
used in this study, but has also been described in other cells
such as smooth muscle cells (Clesham et al., 1996) or primary
cardiac fibroblasts (Maass et al., 2003). A regulation might be
caused by various stimuli, such as -interferon (Acsadi et al.,
1998; downregulation), PMA/forskolin (Clesham et al., 1996;
induction) in various cell types and the CMV promoter has also
been shown to be inactivated after in vivo gene transfer into
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FIG. 5. Comparison of two viral and a tissue-specific pro-
moter and stimulation with forskolin and phorbol-myristate-ac-
etate (PMA) for 48 h, 18 h after transfection with plasmid/
polylysine/adenovirus complexes.
mouse liver (Löser et al., 1997). In the present study, we show
dose-dependent induction of this promoter in a plasmid back-
ground by PMA and forskolin in cardiomyocytes. The mecha-
nism of this induction, however, remains unclear. An increase
in the actual uptake of the complexes or adenoviruses and
thereby increase in gene transfer efficiency appears unlikely be-
cause the substances were added 18 h after the transfection/in-
fection and after the cells had been washed with fresh media.
One might argue that the uptake of complexes still attached to
the cell membrane after washing was facilitated. It has been
shown, however, that adenovirus uptake into cells is very rapid
(Greber et al., 1993), and is usually completed after a few hours.
The prolongation of the previously described short half-life of
luciferase in mammalian cells of about 3 h (Thompson et al.,
1991) by these substances is also not likely, since the effect was
also seen with -galactosidase, a protein with much longer half-
life. The most likely explanation is the induction or activation
of specific transcription factors stimulating transcription from
the CMV early promoter. Binding sites for multiple transcrip-
tion factors have been identified in this promoter, some like
cAMP response element binding protein (CREBP) (Stam-
minger et al., 1990) and serum response factor (Chan et al.,
1996) being implicated in stimulation, while YY1 is thought to
be a negative regulator (Liu et al., 1994). Phorbol esters are in-
ducers of the signal transduction molecule protein kinase C that
induces multiple cellular pathways including the transcription
factor NFB. Forskolin leads to increased cellular cAMP lev-
els that induce protein kinase A and the transcription factor
CREBP.
An interesting and surprising finding of this study is that a
high percentage of neonatal rat CMCs is silently transfected.
This inactivation can be overcome by treatment with PMA
and/or forskolin. Inactivation of the CMV promoter has been
described in vivo after adenoviral infection of the mouse liver
(Löser et al., 1997). This could be overcome by reinfection with
an “empty” replication-deficient adenovirus. The likely molec-
ular mechanism was the induction of the transcription factor
NFB. This transcription factor is ubiquitously expressed in
resting CMCs but at a very low level, and is increased in
(patho)physiological conditions such as ischemia and aging
(Helenius et al., 1996). The abundance of other transcription
factors with demonstrated binding to and activation of the CMV
promoter are also low in normal CMCs, whereas the transcrip-
tion factor YY1 is of high abundance in neonatal cardiomy-
ocytes (Patten et al., 2000). This expression pattern of tran-
scription factors in neonatal cardiomyocytes possibly tips the
balance between positive and negative transcriptional regula-
tors towards the latter. Preliminary experiments with transcrip-
tion factor decoy using the repeat elements point to an in-
volvement of YY-1 and NFB (data not shown).
In conclusion, we determined the critical parameters for the
use of adenovirus/polylysine/DNA complexing for gene trans-
fer to cardiac myocytes. Furthermore, the induction of the CMV
promoter demonstrated here is important to take into consider-
ation when using this promoter in gene transfer experiments.
Caution should be used when the CMV promoter is employed
as normalization for studies involving analyses of regulatory el-
ements. Another direct consequence of our results is that gene
expression can be enhanced dramatically in cardiomyocytes by
well-defined substances with low toxicity. If uninducible, but
lower expression is required, the RSV promoter should be con-
sidered. Further experiments are aimed at validation of CMV
promoter regulation in vivo and preliminary results show an in-
duction of the CMV promoter by hypertrophic stimuli after di-
rect plasmid injection in vivo.
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